subscribeSubscribe
The China NMPA Approved CYRAMZA for the Treatment of Hepatocellular Carcinoma

The China NMPA Approved CYRAMZA for the Treatment of Hepatocellular Carcinoma
PRNEWSWIRE
09 Oct 2022
Share Share
Eli Lilly`s Biologic Cyramza (Ramucirumab) Receives Approval in the U.S.

Eli Lilly`s Biologic Cyramza (Ramucirumab) Receives Approval in the U.S.
FDA
22 Mar 2022
Share Share
Pieris Pharma Announces First Patient Dosed Phase 2 Gastric Cancer

Pieris Pharma Announces First Patient Dosed Phase 2 Gastric Cancer
TRIALSITENEWS
14 Jan 2022
Share Share
Edesa finds a signal in severely ill Covid-19 patients

Edesa finds a signal in severely ill Covid-19 patients
Elizabeth Cairns EVALUATE
21 Sep 2021
Share Share
Lilly 483 report offers insights from site making COVID antibodies

Lilly 483 report offers insights from site making COVID antibodies
Joanne S. Eglovitch RAPS
12 Aug 2021
Share Share
FDA issues form 483 to Eli Lilly

FDA issues form 483 to Eli Lilly

FDA
12 Aug 2021
Share Share
Eli Lilly`s Biological Ramucirumab Receives Supplemental Approval In US

Eli Lilly`s Biological Ramucirumab Receives Supplemental Approval In US
FDA
17 Jun 2021
Share Share
ALX Oncology to Collaborate with Lilly to Evaluate ALX148 in Combinations

ALX Oncology to Collaborate with Lilly to Evaluate ALX148 in Combinations
BIOSPACE
10 Jun 2021
Share Share
Basilea announces Clinical Trial Collb and Supply Agreement with Eli Lilly

Basilea announces Clinical Trial Collb and Supply Agreement with Eli Lilly
GLOBENEWSWIRE
27 Oct 2020
Share Share
PIERIS & LILLY ENTER INTO A CLINICAL TRIAL COLLABORATION TO EVALUATE OF PRS-343

PIERIS & LILLY ENTER INTO A CLINICAL TRIAL COLLABORATION TO EVALUATE OF PRS-343
PRESS RELEASE
10 Aug 2020
Share Share